- $2.86bn
- $2.49bn
- $587.86m
Annual income statement for Hinge Health, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K |
| Standards: | USG | USG | USG |
| Status: | Final | Final | Final |
| Revenue | |||
| Total Revenue | 293 | 390 | 588 |
| Cost of Revenue | |||
| Gross Profit | 194 | 301 | 468 |
| Selling / General / Administrative Expenses | |||
| Research And Development | |||
| Unusual Expense / Income | |||
| Total Operating Expenses | 423 | 422 | 1,134 |
| Operating Profit | -131 | -31.9 | -546 |
| Other Net Non Operating Costs | |||
| Net Income Before Taxes | -109 | -11.3 | -527 |
| Provision for Income Taxes | |||
| Net Income After Taxes | -108 | -11.9 | -528 |
| Net Income Before Extraordinary Items | |||
| Net Income | -108 | -11.9 | -528 |
| Adjustments to Net Income | |||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | -108 | -11.9 | -424 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | -1.39 | -0.091 | -7.71 |